RxDoctor Payments Data

Thomas Wieme, PA

Physician Assistant · Augusta, GANPI 1427207422

Payments from drug & device makers

$9,206in general payments, 2019–2025

Across 463 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Lilly USA, LLC$890
  • GSK$620
  • Pfizer$402
  • AstraZeneca$399
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$9,206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,206 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$67,689
Medicare patients
177
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$106,258
RybelsusSemaglutide44$96,089
OzempicSemaglutide50$79,108
EliquisApixaban72$58,800
JardianceEmpagliflozin42$41,732
JanuviaSitagliptin Phosphate33$33,593
MyrbetriqMirabegron36$28,329
FarxigaDapagliflozin Propanediol24$21,833
ShingrixVaricella-Zoster Ge/As01b/Pf93$20,660
TradjentaLinagliptin13$16,142
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$15,271
Combivent RespimatIpratropium/Albuterol Sulfate29$14,980
TrulicityDulaglutide12$13,567
Tresiba Flextouch U-200Insulin Degludec16$13,011
Nurtec OdtRimegepant Sulfate11$10,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$2,012$175,19794 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$620$162,913237 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$233$72,85484 claims
PfizerEliquis, Nurtec Odt$402$69,79083 claims
MerckJanuvia$27$33,59333 claims
AstraZenecaFarxiga, Symbicort$399$29,45749 claims
Astellas Pharma US IncMyrbetriq$114$28,32936 claims
Lilly USA, LLCTrulicity$890$13,56712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →